Evidence map›Paper›PMID 39881068›Full record

ArticleInternational ophthalmology2025

Orbital inflammatory disease: a joint clinical experience in rheumatology and ophthalmology.

Semih Gülle, Ceren Durmaz Engin, Denizcan Özizmirliler, Süleyman Men, Fatoş Önen, Meltem Söylev Bajin

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Semih GülleDepartment of Rheumatology, Dokuz Eylul University School of Medicine, Dokuz Eylül Üniversitesi Hastanesi, İnciraltı Mah, Balçova, Izmir, Turkey. semih.gulle@hotmail.com.ORCID https://orcid.org/0000-0001-8679-2130
Ceren Durmaz EnginDepartment of Ophtalmology, Buca Seyfi Demirsoy Education and Research Hospital, Izmir, Turkey.ORCID https://orcid.org/0000-0001-5797-6467
Denizcan ÖzizmirlilerDepartment of Ophtalmology, Dokuz Eylul University School of Medicine, Izmir, Turkey.ORCID https://orcid.org/0000-0001-9368-9764
Süleyman MenDepartment of Radiology, Dokuz Eylul University School of Medicine, Izmir, Turkey.ORCID https://orcid.org/0000-0002-8221-3194
Fatoş ÖnenDepartment of Rheumatology, Dokuz Eylul University School of Medicine, Dokuz Eylül Üniversitesi Hastanesi, İnciraltı Mah, Balçova, Izmir, Turkey.ORCID https://orcid.org/0000-0002-6341-2622
Meltem Söylev BajinDepartment of Ophtalmology, Dokuz Eylul University School of Medicine, Izmir, Turkey.ORCID https://orcid.org/0000-0002-8052-9558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis retrospective study aimed to characterize the clinical features, histopathological findings, and treatment outcomes of patients diagnosed with orbital inflammatory disease (OID) co-managed by the rheumatology and ophthalmology departments in a tertiary hospital.

methodsMedical records of 14 patients with OID were analyzed. Data on demographics, clinical presentation, laboratory investigations, radiological imaging, histopathological results, treatment regimens, and disease outcomes were collected and reviewed.

resultsThe mean age of the patients was 34.5 years, with a female (71.4%) predominance. Periorbital pain (62.5%), periorbital edema (50%) and diplopia (50%) were the most common presenting symptoms. Histopathological evaluation revealed diverse subtypes, including non-specific orbital inflammation (NSOI) (42.8%), orbital myositis (28.5%) and IgG4-related disease (14.3%). Initial treatment with systemic corticosteroids achieved remission in 14.3% of patients, while 85.7% required additional immunosuppressive therapy. Radiotherapy was effective in one patient unresponsive to steroid and azathioprine treatment.

conclusionOID presents with diverse clinical manifestations and histopathological subtypes, often requiring multidisciplinary management. While corticosteroids remain the first-line therapy, adjunctive immunosuppressive agents or radiotherapy may be necessary in refractory cases.

Indexed as

OphthalmologyOrbital MyositisOrbital PseudotumorRheumatologyAdolescentAdultFemaleGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedYoung AdultGlucocorticoidsImmunosuppressive AgentsIgG4OIDOrbital massOrbital myositisRheumatic diseases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.